Overview

Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Endo Pharmaceuticals
Collaborator:
Alkermes, Inc.
Treatments:
Trospium chloride